---

Background and purpose: Trigonellafoenum-graecum seed has galactogogues properties due to phytoestrogens structure and can increase the volume of breast milk. This study aimed to evaluate the effect of herbal tea containing Trigonellafoenum-graecum seed consumed by mothers on growth parameters of baby girls (0-4 months of age) attending health centers in south of Tehran, 2014. Materials and methods: This clinical trial study was performed in 78 mothers breast feeding their 0-4 month old baby girls. They were randomly assigned into two groups (n=39 per groups). The intervention group received herbal tea containing 7.5g Trigonellafoenum-graecum seed powder and 3g black tea and the control group received herbal tea containing 3g black tea powder. The mothers used the beverages three times a day for 4 weeks,. The weight, height and head circumference of the babies were measured using baby weight measurement scale, stadiometer and tape measure in the beginning of the study and each week until 4 weeks. Data was analyzed by independent sample t test and repeated measurement test in SPSS. Results: No significant difference was found between the two groups in weight, height and head circumference before the intervention (P>0.05). After four weeks Trigonellafoenum-graecum significantly increased the babies’ weight from 5282.05 ± 1021.51 to 6383.07 ± 952.06 and head circumference from 38.31 ± 1.62 to 39.92 ± 1.50 (P<0.001), but it had no effect on the height of studied girls (P=0.078). Conclusion: The results showed that consumption of Trigonellafoenum-graecum seed-containing herbal tea by mothers could improve the weight and head circumference of breastfed babies. (Clinical Trials Registry Number: IRCT201312102751N10)

---

Background and purpose: Parents of children with attention deficit hyperactivity disorder (ADHD) have more problems than parents of normal children due to the prevalence of behavioral abnormalities in children with ADHD. Mood disorders in parents, including mothers can lead to lower tolerance thresholds and the use of punitive methods to control the children, which can cause other complications. Therefore, evaluation of mood disorders and timely treatment could be of great help in treating these children and improving the prognosis of the disease.
Materials and methods: This cross-sectional study was conducted in 125 mothers of children with ADHD attending two psychiatric clinics in Babol, Iran 2014-2016. Data were collected using the Conners' Parent Rating Scales - Revised (CPRS-R) and Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I). Data analysis was done in SPSS V22.
Results: The prevalence of mood disorders in mothers of 6-14 year-old children with ADHD was 44% (n=55). Among the mood disorders, dysthymia (27%) was the most common disorder. Forty-five mothers (36%) had depression and 9 (7.2%) had bipolar disorder.
Conclusion: According to current study, depression was the most common mood disorder in mothers. Maternal depression influences the management of a child with ADHD, so, early diagnosis and treatment of maternal depression play major roles in the prognosis of ADHD in a child with this disorder.
 

---

 Background and purpose: Electroconvulsive therapy (ECT) is commonly used in the treatment of psychiatric patients. However, it may cause cognitive disorders in patients undergoing the procedure. The aim of this study was to investigate the effect of memantine on the alleviation of cognitive impairments in patients undergoing ECT.
Materials and methods: In this triple-blind clinical trial, 60 patients with depression phase of unipolar or bipolar non polycystic disorder were randomly divided into two groups of 30. In the treatment group, the patients received memantine for the whole period of treatment starting 24 hours before ECT (starting dose 10 mg/day, increased to 20 mg/day within one week) and continuing until the sixth session of ECT. In the control group, the patients received the placebo. The cognitive performance of patients was assessed using the Mini Mental Status Examination (MMSE) and the Addenbrooke's Cognitive Examination (ACE) 24 hours before the first ECT session, 24 hours after the sixth ECT session, and one month after the end of the ECT sessions. The study lasted 1.5 years.
Results: The MMSE score at the end of the study period (one month after the completion of ECT) in the memantine group was significantly higher than the control group (P=0.008). However, there was no significant difference between the scores of ACE-R between the two groups after ECT. No significant relationship was found between the two groups in any of ACE-R items.
Conclusion: According to the MMSE test, it seems that memantine reduces cognitive disorders in patients receiving ECT, but this finding was not observed in ACE-R.